Sierra Capital’s AbbVie ABBV Stock Holding History

Sierra Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$304K	Hold	1,209	–	–	0.03%	195
2026 Q1	$263K	Buy	+1,209	New	+$268K	0.03%	199
2023 Q1	–	Sell	-2,136	Closed	-$345K	–	185
2022 Q4	$345K	Hold	2,136	–	–	0.06%	143
2022 Q3	$287K	Hold	2,136	–	–	0.05%	153
2022 Q2	$327K	Sell	2,136 -3	-0.1%	-$458	0.06%	155
2022 Q1	$347K	Hold	2,139	–	–	0.05%	161
2021 Q4	$290K	Buy	2,139 +826	+63%	+$97.6K	0.04%	187
2021 Q3	$142K	Hold	1,313	–	–	0.02%	232
2021 Q2	$148K	Hold	1,313	–	–	0.03%	208
2021 Q1	$142K	Buy	+1,313	New	+$140K	0.03%	211

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sierra Capital's ABBV Position: Q2 2026 in Review

Sierra Capital held its AbbVie (ABBV) position steady in Q2 2026 at 1,209 shares worth $304K. The position accounts for 0.03% of the portfolio, ranked #195.

Sierra Capital first reported a position in ABBV in Q1 2021 and has held it in 10 quarters since. The position peaked at $347K in Q1 2022. 4,190 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Sierra Capital held 1,209 shares of AbbVie worth $304K as of Q2 2026.
Sierra Capital left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.03% of Sierra Capital's portfolio in Q2 2026, its #195 holding.
Sierra Capital first reported a position in AbbVie in Q1 2021 and has held it in 10 quarters since.
Sierra Capital's AbbVie position peaked at $347K in Q1 2022.
4,190 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Sierra Capital's 13F filing for Q2 2026, filed 14 Aug 2026.